Arrowhead Pharmaceuticals Publishes Presentation on Plozasiran's Reduction of Acute Pancreatitis Risk

• Arrowhead Pharmaceuticals published a medical research presentation on pooled results from the phase 3 SHASTA-3 and SHASTA-4 plozasiran trials.
• Plozasiran reduced acute pancreatitis event rates to 1% versus 5.1% with placebo over 12 months; relative risk was 0.22 (P=0.008).
• Quarterly dosing produced sustained triglyceride reductions of about 80%; more than 90% of patients achieved levels below 500 mg/dL.
• Among patients with prior pancreatitis, event rates were 3.3% with plozasiran versus 37.1% with placebo.
• Worsening glycemic control occurred in 14% of plozasiran patients versus 9% with placebo; overall adverse event rates were generally similar.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief on November 08, 2026, and is solely responsible for the information contained therein.